Additional file 1: of TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines

Table S1 Histopathological and follow-up information of the 64 MM patients included in the study. Table S2 Genomic amplification hotspots in MM and association test with tumor thickness, related to Figure 1. Table S3 CGH array data of NTRK1 and CDKN2A for 31 primary MM specimens (from GEO Series GSE45354). Table S4 Validation of the aCGH analysis by genomic qPCR, related to Figure 2 and Figure S1. Table S5 Copy number and mRNA expression data for NTRK1 in CCLE melanoma cell lines, related to Figure S2. Table S6 Copy number, mRNA expression, and clinical stage data for NTRK1 in TCGA melanoma samples, related to Figure S2.

补充表S1 本研究纳入的64例恶性黑色素瘤（MM, Malignant Melanoma）患者的组织病理学与随访信息。
补充表S2 恶性黑色素瘤（MM）的基因组扩增热点及其与肿瘤厚度的关联分析数据，对应图1。
补充表S3 取自GEO数据集GSE45354的31例原发性恶性黑色素瘤标本的NTRK1与CDKN2A比较基因组杂交（CGH, Comparative Genomic Hybridization）芯片数据。
补充表S4 利用基因组定量聚合酶链反应（qPCR, quantitative PCR）验证阵列比较基因组杂交（aCGH, array-based Comparative Genomic Hybridization）分析结果的相关数据，对应图2及补充图S1。
补充表S5 癌细胞系百科全书（CCLE, Cancer Cell Line Encyclopedia）黑色素瘤细胞系中NTRK1的拷贝数与mRNA表达数据，对应补充图S2。
补充表S6 癌症基因组图谱（TCGA, The Cancer Genome Atlas）黑色素瘤样本中NTRK1的拷贝数、mRNA表达及临床分期数据，对应补充图S2。